---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-261696"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2026-06-08T20:05:15+00:00"
generated_at: "2026-06-08T20:06:20.677318+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics shareholders approve doubling of authorized shares to 400M

## Summary
- Shareholders elected David Lubner, Brian Posner, Jason Rhodes as Class III directors to three-year terms.
- Non-binding advisory vote approved executive compensation with ~98% of votes cast in favor.
- Authorized common stock doubled from 200M to 400M shares via charter amendment filed June 8.
- Charter amended to include officer exculpation provision limiting personal liability.
- Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2026.

## SEC filing metadata
- accession: 0001193125-26-261696
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2026-06-08T20:05:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/0001193125-26-261696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/dyn-20260605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-261696
- JSON: https://secwatch.observer/filing/0001193125-26-261696.json
- Plain text: https://secwatch.observer/filing/0001193125-26-261696.txt

## Key facts
- Shareholder Votes
  Dyne Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-05 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/0001193125-26-261696-index.htm
- Shareholder Votes
  Dyne Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-05 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/0001193125-26-261696-index.htm
- Shareholder Votes
  Dyne Therapeutics, Inc. shareholders approved Election of Class III directors at the 2026-06-05 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: The stockholders of the Company elected David Lubner, Brian Posner and Jason Rhodes as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/0001193125-26-261696-index.htm
- Shareholder Votes
  Dyne Therapeutics, Inc. shareholders approved Approval of amendment to restated certificate of incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares at the 2026-06-05 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: The stockholders of the Company approved an amendment to the Company’s restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (the “Authorized Shares Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/0001193125-26-261696-index.htm
- Shareholder Votes
  Dyne Therapeutics, Inc. shareholders approved Approval of amendment to restated certificate of incorporation to provide for officer exculpation at the 2026-06-05 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: The stockholders of the Company approved an amendment to the Company’s restated certificate of incorporation to provide for officer exculpation (the “Officer Exculpation Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/0001193125-26-261696-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.